Deciphering the Heterogeneity Within EGFR-mutant Lung Cancer

from Journal of Clinical Oncology (JCO) Podcast · host Geoffrey R. Oxnard

A meta-analysis of 7 randomized trials comparing EGFR kinase inhibitors to chemotherapy for advanced EGFR-mutant lung cancer has shown that some populations gain greater benefit from targeted therapy – namely never-smokers, woman, and tumor harboring exon 19 deletions.

Episode metadata supplied by the publisher feed · Published Apr 20, 2015

Embed this episode

Attribution link and audio player

NOW PLAYING

Deciphering the Heterogeneity Within EGFR-mutant Lung Cancer

0:00 6:54

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Journal of Clinical Oncology (JCO) Podcast?

This episode is 6 minutes long.

When was this Journal of Clinical Oncology (JCO) Podcast episode published?

This episode was published on April 20, 2015.

Can I download this Journal of Clinical Oncology (JCO) Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!